Literature DB >> 31746697

A Validation Study of the Remotely Administered Montreal Cognitive Assessment Tool in the Elderly Japanese Population.

Kiyoko Iiboshi1, Kazunari Yoshida2,3, Yoshitaka Yamaoka2, Yoko Eguchi2, Daisuke Sato4, Megumi Kishimoto5, Kei Funaki2, Masaru Mimura2, Taishiro Kishimoto2,6,7,8.   

Abstract

Background: In an aging society, neuropsychological testing using video teleconferencing (VTC) is increasingly important. Despite the potential benefit of a VTC-administered Montreal Cognitive Assessment Tool (MoCA) to detect cognitive decline, only a limited number of studies have investigated this tool's reliability. Therefore, we aimed to evaluate the reliability of VTC-administered MoCA compared with face-to-face (FTF)-administered MoCA among elderly Japanese participants. Moreover, we examined participants' satisfaction with VTC-administered MoCA.
Methods: Participants ≥60 years of age with and without cognitive impairment (i.e., those with mild cognitive impairment [MCI], those with dementia, and healthy controls [HC]) were assessed with VTC- and FTF-administered MoCA at an interval of >2 weeks and <3 months. The order effect (VTC first vs. FTF first) and time effect (first vs. second testing session), as well as several covariates such as age and years of education were controlled. Intraclass correlation coefficients (ICCs) were calculated using a mixed-effects model to assess the agreement between the two (VTC- vs. FTF-administered) groups. Participants' satisfaction with VTC-administered MoCA was examined using a Likert scale asking seven questions.
Results: We included 73 participants in the study (36 men; age, 76.3 ± 7.5 years). The ICC for the MoCA total score was high in the entire sample (0.85), whereas ICCs were moderate to high for the subgroups (MCI: 0.82, dementia: 0.82, and HC: 0.53). Furthermore, we found good overall participant satisfaction with VTC-administered MoCA. Discussion: VTC-administered MoCA appears viable as an alternative to FTF-administered MoCA, although further replication studies with larger sample sizes are needed.

Entities:  

Keywords:  Alzheimer's disease; MoCA; mild cognitive impairment; neuropsychological tests; telepsychiatry

Mesh:

Year:  2019        PMID: 31746697     DOI: 10.1089/tmj.2019.0134

Source DB:  PubMed          Journal:  Telemed J E Health        ISSN: 1530-5627            Impact factor:   3.536


  9 in total

1.  Correlation of vascular change and cognitive impairment in age-related macular degeneration patients.

Authors:  Yaoyan Qiu; Tingting Sun; Feijia Xu; Peng Gao; Guangyu Tang; Qing Peng
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  A hierarchy of needs for remote undergraduate medical education: lessons from the medical student experience.

Authors:  Henrike C Besche; Sarah Onorato; Stephen Pelletier; Sepideh Ashrafzadeh; Ashwini Joshi; Brenna Nelsen; Jaewon Yoon; Joyce Zhou; Andrea Schwartz; Barbara A Cockrill
Journal:  BMC Med Educ       Date:  2022-06-02       Impact factor: 3.263

Review 3.  Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond.

Authors:  Paula J Gosse; Charles D Kassardjian; Mario Masellis; Sara B Mitchell
Journal:  CMAJ       Date:  2021-03-15       Impact factor: 8.262

4.  T-MoCA: A valid phone screen for cognitive impairment in diverse community samples.

Authors:  Mindy J Katz; Cuiling Wang; Caroline O Nester; Carol A Derby; Molly E Zimmerman; Richard B Lipton; Martin J Sliwinski; Laura A Rabin
Journal:  Alzheimers Dement (Amst)       Date:  2021-02-05

5.  Videoconference version of the Montreal Cognitive Assessment: normative data for Quebec-French people aged 50 years and older.

Authors:  Christine Gagnon; Miloudza Olmand; Emma Gabrielle Dupuy; Florent Besnier; Thomas Vincent; Catherine-Alexandra Grégoire; Marianne Lévesque; Marie Payer; Béatrice Bérubé; Juliana Breton; Catia Lecchino; Nadia Bouabdallaoui; Josep Iglesies-Grau; Mathieu Gayda; Paolo Vitali; Anil Nigam; Martin Juneau; Carol Hudon; Louis Bherer
Journal:  Aging Clin Exp Res       Date:  2022-02-18       Impact factor: 3.636

6.  Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease.

Authors:  Charles F Murchison; Byron C Jaeger; Jeff M Szychowski; Gary R Cutter; Erik D Roberson; Richard E Kennedy
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

7.  The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments.

Authors:  Varna Jammula; James L Rogers; Elizabeth Vera; Alexa Christ; Heather E Leeper; Alvina Acquaye; Nicole Briceno; Anna Choi; Ewa Grajkowska; Jason E Levine; Matthew Lindsley; Jennifer Reyes; Kayla N Roche; Michael Timmer; Lisa Boris; Eric Burton; Nicole Lollo; Marissa Panzer; Matthew A Smith-Cohn; Marta Penas-Prado; Valentina Pillai; Brett J Theeler; Jing Wu; Mark R Gilbert; Terri S Armstrong
Journal:  Neurooncol Pract       Date:  2022-05-14

8.  Patient-Tailored, Home-Based Non-invasive Brain Stimulation for Memory Deficits in Dementia Due to Alzheimer's Disease.

Authors:  Lucie Bréchet; Wanting Yu; Maria Chiara Biagi; Giulio Ruffini; Margaret Gagnon; Brad Manor; Alvaro Pascual-Leone
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

Review 9. 

Authors:  Paula J Gosse; Charles D Kassardjian; Mario Masellis; Sara B Mitchell
Journal:  CMAJ       Date:  2021-06-07       Impact factor: 8.262

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.